Analyst Ratings For NASDAQ:STML – Stemline Therapeutics (NASDAQ:STML)
Today, Roth Capital initiated coverage on NASDAQ:STML – Stemline Therapeutics (NASDAQ:STML) with a Buy with a price target of $30.00.
Some recent analyst ratings include
- 6/12/2018-Roth Capital initiated coverage with a Buy rating.
- 5/10/2018-Cowen Reiterated Rating of Buy.
- 5/25/2017-Jefferies Financial Group Reiterated Rating of Buy.
Recent Insider Trading Activity For NASDAQ:STML – Stemline Therapeutics (NASDAQ:STML)
NASDAQ:STML – Stemline Therapeutics (NASDAQ:STML) has insider ownership of 14.80% and institutional ownership of 66.91%.
- On 3/13/2018 Kenneth Hoberman, COO, sold 29,987 with an average share price of $17.14 per share and the total transaction amounting to $513,977.18.
- On 3/12/2018 David Gionco, Insider, sold 9,183 with an average share price of $17.38 per share and the total transaction amounting to $159,600.54.
- On 3/12/2018 Ivan Bergstein, CEO, sold 37,857 with an average share price of $17.34 per share and the total transaction amounting to $656,440.38.
- On 3/7/2018 David Gionco, Insider, sold 1,413 with an average share price of $16.56 per share and the total transaction amounting to $23,399.28.
- On 3/7/2018 Ivan Bergstein, CEO, sold 6,797 with an average share price of $16.56 per share and the total transaction amounting to $112,558.32.
- On 3/7/2018 Kenneth Hoberman, COO, sold 3,027 with an average share price of $16.55 per share and the total transaction amounting to $50,096.85.
- On 2/27/2018 David Gionco, Insider, sold 8,984 with an average share price of $17.43 per share and the total transaction amounting to $156,591.12.
Recent Trading Activity for NASDAQ:STML – Stemline Therapeutics (NASDAQ:STML)
Shares of NASDAQ:STML – Stemline Therapeutics closed the previous trading session at 18.65 up +0.75 4.19% with 18.450000762939453 shares trading hands.